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Abstract
Background: Malaria parasites that carry the DHFR-mutation I164L are not only highly resistant
to sulfadoxine-pyrimethamine but also to the new antimalarial drug chlorproguanil-dapsone. The
spread of this mutation in Africa would result in a public health disaster since there is a lack of
effective alternatives that are both affordable and safe. Up to now, this mutation has only been
described in Asian and Latin-American countries. The objective of this study was to assess the
prevalence of this mutation in African isolates of Plasmodium falciparum that have been imported
into Europe through travellers.
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Methods: TropNetEurop is a network for the surveillance of travel-associated diseases and seems
to cover approximately 12% of all malaria cases imported into Europe. Within this network we
screened 277 imported African isolates of P. falciparum with the help of PCR- and enzyme-
digestion-methods for the antifolate-resistant mutation I164L.
Results: The I164L mutation was not detected in any of the isolates tested.
Discussion: Continuous molecular surveillance of mutations in P. falciparum, as it is practised
within TropNetEurop, is an essential tool for the understanding and early detection of the spread
of antimalarial drug resistance in Africa.
Background
Drug resistant malaria is a major problem in malaria con-
trol. At the present, there are few antimalarial drugs avail-
able in endemic areas which are both cheap and save.
Since resistance to chloroquine has spread across sub-
Saharan Africa, several countries have switched their first-
line drug to the antifolate sulfadoxine-pyrimethamine [1].
Soon after sulfadoxine-pyrimethamine was introduced to
malaria-control programs in the late 1960s, resistance to
this drug was noted [2]. The efficacy of sulfadoxine-
pyrimethamine primarily depends on the sensitivity of
the parasite to pyrimethamine [3]. The dihydrofolate
reductase domain of Plasmodium falciparum (pfDHFR) is
the target of this drug. DHFR catalyzes the reduction of
dihydrofolate to regenerate tetrahydrofolate which is
required for one-carbon transfer reactions and deox-
ythymidylate synthesis of the parasites.
The discovery of changes in codons of the pfDHFR-gene
strongly indicated that single amino acid changes lead to
observed resistance. Mutations at amino acid position 51,
59, 108 and 164 have been shown to be linked with resist-
ance of P. falciparum to antifolate antimalarials. A scheme
for evolution of resistance could be derived as a result of
stepwise mutations starting with the S108N mutation,
which was shown to be the optimal mutation in leading
to both the decreased binding affinity for inhibitors and
the retention of enzyme activity [4,5]. Absolute resistance
is conferred by the addition of I164L mutation in the
quadruple mutant form (N108/I51/R59/L164). In this
fourth mutation the enzyme is about 1,000-fold less sen-
sitive to pyrimethamine [6].
The I164L mutation also plays an important role in the
development of resistance to the more potent antifolate
combination chlorproguanil-dapsone: while the triple
mutant allele (N108/I51/R59) has no great impact on the
sensitivity of this drug, parasites that carry the quadruple
mutant allele are resistant [7,8]. This highly potent quad-
ruple mutation was described first in South East Asia, later
also in South America [9–11]. There is a concern that con-
tinued sulfadoxine-pyrimethamine pressure, as well as the
widespread use of trimethoprim-sulfamethoxazole for
prophylaxis against opportunistic infections in patients
with AIDS in Africa, is going to select these highly resistant
alleles [12]. This would rapidly make sulfadoxine-
pyrimethamine, as well as chlorproguanil-dapsone, inef-
fective in this region. For this reason continued surveil-
lance of this mutation is needed to evaluate the
prevalence, the distribution and the speed with which
these populations might be selected.
TropNetEurop is a European surveillance system that cov-
ers approximately 12% of all imported malaria cases in
Europe [13]. Travellers can be used as a highly sensitive
surveillance tool to detect development of drug-resistance
in endemic areas, as it is suggested that most of them carry
a monoclonal Plasmodium strain. Initial data on molecu-
lar surveillance, not including the I164L mutation, have
already been published elsewhere [14].
Since there are only limited data available on the preva-
lence of the I164L mutation throughout Africa, the pur-
pose of this survey was to screen a sample of P. falciparum
imported from Africa for this particular antifolate
mutation.
Material and methods
Sampling
The European Network on Imported Infectious Disease
Surveillance (TropNetEurop) has been established in
1999 and, in 2001, covered approximately 12% of all
imported malaria cases in Western and Central Europe
[13]. At the present 45 clinical sites in Europe are mem-
bers of the network with more than 57,000 patients seen
post-travel annually.
Within the infrastructure of TropNetEurop several mem-
ber sites started in 2001 to collect blood samples from
patients diagnosed with a P. falciparum infection. 10 µl of
whole blood from each patient were dotted on Whatman
3 MM® chromatography paper and air-dried at room tem-
perature before initiation of treatment. The filter paper
disks were sent to Munich for further preparation.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/17
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For this survey we screened all blood samples that were
obtained between January 2001 and July 2002 from trav-
ellers returning from Africa with a microscopically con-
firmed P. falciparum infection.
Parasite DNA and Polymerase chain reaction
Parasite DNA was prepared from the dried blood spots on
the filter paper by the Chelex method as described by Kain
and Lanar [15]. Nested mutation-specific PCR was done
as previously described for analysis of the DHFR 164
mutation site [16,17].
Restriction fragment length polymorphisms
A volume of 4 µl of PCR product was incubated for three
hours at a temperature of 37°C with the mutation specific
restriction enzyme DraI according to the manufacturer's
instructions (New England Biolabs, Beverly, MA, USA). To
discriminate between the two variants of codon 164, the
522 bp PCR product was digested with DraI to detect the
leucine mutation (143 bp). The digestion products were
separated by electrophoresis in a 1% SeaKem™ plus 1%
NuSieve™ gel (FMC BioProducts, Rockland, ME, USA)
containing ethidium bromide. DNA from established lab-
oratory strains of P. falciparum served as controls of PCR
and enzyme digests. Gels were recorded by photography.
Results
Over the 18-month time period we collected 277 blood
samples from patients with a microscopically confirmed
P. falciparum infection acquired in Africa. The DNA from
all blood samples was amplified by nested PCR systems as
described above. 271 samples showed the expected bands
at 522 bp for the DHFR gene, while six samples turned out
to be negative for P. falciparum DNA.
Among the 271 observed samples of P. falciparum, 170
(62.7%) were imported from West Africa, 46 (16.6%)
from East Africa, 36 (13%) from Central Africa, 17 (6.1%)
from South Africa and two from Madagascar (Tab 1).
After digestion none of the 271 isolates revealed the leu-
cine-164 mutation. All 271 isolates of P. falciparum pre-
sented as the wild type with the amino acid isoleucine in
position 164.
Discussion
The burden of falciparum malaria is carried mainly by
tropical Africa. Since resistance to Chloroquine is now
widespread in Africa, the antifolate combination sulf-
adoxine-pyrimethamine (SP) is often the only affordable
alternative.
Unfortunately, SP is particularly prone to the rapid emer-
gence of resistance [18]. There is evidence, that in vitro
pyrimethamine chemosensitivity will be predictive of in
vivo  SP efficacy, and that parasitological resistance in
Africa is primarily due to the triple mutant in DHFR:
S108N, N51I and C59R [19–21].
At the moment, the only drug available in Africa to deal
with SP failure is often further treatment with SP.
Researchers are, therefore, seeking new, safe and inexpen-
sive, second line drugs or combination regimens. Among
these regimes chlorproguanil-dapsone is considered a
potential replacement for SP in Africa because of its effec-
tiveness against infections associated with triple mutants
in DHFR, its short half-life and its low price [21–23].
However, the efficacy of combinations involving old
drugs may be short-lived, since resistance-conferring
mutations already exist. In the case of chlorproguanil-
dapsone, the change in DHFR enzyme structure resulting
from the I164L mutation is known to be associated with
resistance to this drug [19,20].
Experience with SP in South East Asia and South America
has shown that continued use of SP will select for the
quadruple mutant DHFR, including I164L. So far, muta-
tions of this potency have not been observed in Africa in
any study using standard PCR analyses [10,17,21,23–27].
The I164L mutation was also not found in any of the iso-
lates we analyzed within this survey.
Recently, Hastings et al. [28] developed a yeast-based sys-
tem that is sensitive enough to identify point mutations in
Table 1: Frequencies of geographical regions in which the observed Plasmodium falciparum infection has been acquired
Frequency (%) Mutation (%) Wild type (%)
West-Africa 170 (62.7) 0 (0%) 166 (100%)
East-Africa 46 (16.6) 0 (0%) 46 (100%)
Central-Africa 36 (13) 0 (0%) 36 (100%)
South-Africa 17 (6.1) 0 (0%) 17 (100%)
Madagascar 2 (0.7) 0 (0%) 2 (100%)
Total 271 (100) 0 (0%) 271 (100%)
PCR-negative 6Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/17
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the DHFR gene even if they are rare. With the help of this
technique alleles that encoded the I164L mutations were
isolated from 3 of 6 patient samples with SP treatment
failure from Tanzania. However, mutations of all kinds
occur during DNA replication, but not all establish them-
selves and are functional.
Overall, efficient surveillance systems to detect and mon-
itor resistance to SP are required, since malaria infections
will become fully resistant to SP and chlorproguanil-dap-
sone with the selection of the DHFR mutation I164L in
Africa. For this reason, several national and regional net-
works of sentinel sites have been set up in recent years and
collaborate in order to monitor antimalarial drug resist-
ance. The East African Network for Monitoring Antimalar-
ial Treatment (EANMAT), for example, started in 1998 to
monitor drug resistance with standard in vivo tests [29].
TropNetEurop, as the largest network for infectious dis-
eases acquired by travellers worldwide, can function as an
additional sensitive tool in the surveillance of antimalar-
ial drug resistance.
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